Rennaz

This research aims to evaluate how better cooperation between hospital pharmacists and community pharmacists affects the safety of medication management at hospital discharge. The study focuses on adult patients admitted to the internal medicine ward who are taking seven or more medications and are being discharged to their homes. Hospital stays often change patients' medication regimens, and community pharmacies may not always have enough information to safely manage complex discharge prescriptions, which can lead to medication errors and risks to patients. The study compares two groups: one where a hospital pharmacist actively collaborates with the community pharmacy during discharge, and one receiving usual care without this enhanced collaboration. The hospital pharmacist's role includes calling the community pharmacy before discharge to order special medications, performing medication reconciliation with the hospital physician on discharge day, sending the discharge prescription early to the community pharmacy, and providing detailed patient and prescription information to assist the community pharmacist. Participants only need to visit their usual community pharmacy after discharge and agree to have their medical information shared between the hospital and community pharmacy. Researchers will measure the number of drug-related problems found in the discharge prescriptions seven days after hospital discharge. This monitoring helps assess whether improved pharmacist collaboration reduces medication issues and enhances patient safety during the transition home.

Researchers are evaluating the impact of preoperative oral immunonutrition (IN) on complications after cystectomy, a surgery to remove the bladder. This study focuses on patients aged 18 and older undergoing open cystectomy for various bladder diseases. The trial also aims to identify which patients may benefit most from IN. This multicenter, phase 3, randomized controlled trial is conducted at three Swiss centers with a parallel-group design using block randomization. The study compares patients receiving oral immunonutrition, specifically Oral Impact4 by Nestle9 Health Science, taken three times daily for seven days before surgery, against those not receiving this intervention. Oral Impact4 is a powdered feed providing 309 kcal per bag and contains arginine, ribonucleic acid, and omega-3 fatty acids intended to improve nutritional and immune status before surgery. The intervention is given preoperatively to evaluate its effect on postoperative complications and immune response. Participants will be monitored for infectious complications within 30 days following surgery. Researchers will collect data on post-operative outcomes, including infection rates and immune function. The study includes assessments of safety and recovery, with follow-up covering the first month after cystectomy. This trial aims to provide evidence that could lead to changes in clinical guidelines recommending immunonutrition before cystectomy if benefits are demonstrated.